How types of radiation-caused rectal injury relate to recovery and outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational cohort planned to enroll 150 adults with radiation-induced rectal injury beginning in November 2025 at the Sixth Affiliated Hospital, Sun Yat-sen University in Guangzhou. Researchers will not change clinical care but will collect clinical data, endoscopy, imaging, pathology results, laboratory tests, and follow-up information. Clinical subtypes of rectal injury will be classified and correlated with short- and long-term prognosis using this prospectively gathered dataset. The goal is to fill current evidence gaps and provide data to improve diagnosis, monitoring, and management strategies for affected patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18-80 years;
2. Diagnosed with chronic radiation enteropathy.

Exclusion Criteria:

1. Ongoing cancer therapy;
2. Tumor recurrence or metastasis.

Where it's running

• The Sixth Affiliated Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Qiyuan Qin, M.D.
• Email: qinqy3@mail.sysu.edu.cn
• Phone: 86-13580359171

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using dietary supplements to treat rectal injury from radiation

  This study is testing whether a dietary supplement called tributyrin can help people with chronic rectal injury from radiation feel better and improve their quality of life.

  Recruiting Phase 2 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT06776016

• Analysis of outcomes and side effects in patients receiving radiation therapy

  This study looks at the results and side effects of radiation therapy in patients at Winterthur Cantonal Hospital to see how treatment can be improved for future patients.

  Recruiting Kantonsspital Winterthur KSW · Winterthur, Canton of Zurich · NCT05192876

• Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread

  This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07893392

• Tributyrin as a dietary supplement to help prevent radiation-induced rectal injury during rectal cancer chemoradiation

  This study tests whether adding tributyrin to standard chemoradiotherapy helps prevent acute radiation-induced rectal injury in people with locally advanced rectal cancer.

  Recruiting Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07802002

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• Virtual vs in-person follow-up visits after radiotherapy

  This study tests whether telehealth follow-ups during radiotherapy are practical and satisfactory for patients and physicians, compared to in-person visits.

  Recruiting Shaukat Khanum Memorial Cancer Hospital & Research Centre · Lahore, Punjab Province · NCT07724548

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.